ReviewBioMed research international2017
The Strategy to Prevent and Regress the Vascular Calcification in Dialysis Patients.
Review in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Pooled it
- Intravenous sodium thiosulphate for vascular calcification of hemodialysis patients-a systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Pooled it
- Band keratopathy and conjunctival calcification in end-stage kidney disease: epidemiology, pathophysiology and clinical management.Clinical kidney journal · 2026Review
- Article
- PDZ domain containing protein 1 aggravates mouse vascular smooth muscle cells calcification via PDZ1 domain mediated β-catenin stabilization and nuclear translocation.Communications biology · 2025Article
- Balancing accuracy and cost in machine learning models for detecting medial vascular calcification in chronic kidney disease: a pilot study.Scientific reports · 2025Article
- [Etiopathogenetic features of bone metabolism in patients with diabetes mellitus and Charcot foot].Problemy endokrinologii · 2024Review
- Mechanisms of Cardiovascular Calcification and Experimental Models: Impact of Vitamin K Antagonists.Journal of clinical medicine · 2024Review
- Nε-Carboxymethyl-Lysine Mediates Vascular Calcification in Diabetes Caused by Impaired Osteoclastic Resorption Activity Through NFATc1-GNPTAB.Journal of cardiovascular translational research · 2023Article
- Medial artery calcification in peripheral artery disease.Frontiers in cardiovascular medicine · 2023Review
- Arterial calcifications and osteoprotegerin in chronic hemodialysis patients: impact on 6-year survival.International urology and nephrology · 2022Article
- A Retrospective Study of Serum Calcium Status in Tehran, Iran (105,128 Samples, from 2009-2018).Iranian journal of public health · 2022Article
- Dialysate Magnesium and Coronary Artery Calcification, Bone Mineral Density, and Cramping in Maintenance Hemodialysis: A Quasi-experimental Study.Kidney medicine · 2022Article
- KCNJ5 Somatic Mutation Is Associated With Higher Aortic Wall Thickness and Less Calcification in Patients With Aldosterone-Producing Adenoma.Frontiers in endocrinology · 2022Article
- Multitargeted interventions to reduce dialysis-induced systemic stress.Clinical kidney journal · 2021Review
- Medial Arterial Calcification: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2021Review
- Aortic Arch Calcification and Cardiomegaly Are Associated with Overall and Cardiovascular Mortality in Hemodialysis Patients.Journal of personalized medicine · 2021Article
- Bone Fragility Fractures in CKD Patients.Calcified tissue international · 2021Review
- The roles of collagen in chronic kidney disease and vascular calcification.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Causes of Vitamin K Deficiency in Patients on Haemodialysis.Nutrients · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The high prevalence of arterial calcification in end-stage renal disease (ESRD) is far beyond the explanation by common cardiovascular risk factors such as aging, diabetes, hypertension, and dyslipidemia. The finding relies on the fact that vascular and valvular calcifications are predictors of cardiovascular diseases and mortality in persons with chronic renal failure. In addition to traditional cardiovascular risk factors such as diabetes mellitus and blood pressure control, other ESRD-related risks such as phosphate retention, excess calcium, and prolonged dialysis time also contribute to the development of vascular calcification. The strategies are to reverse "calcium paradox" and lower vascular calcification by decreasing procalcific factors including minimization of inflammation (through adequate dialysis and by avoiding malnutrition, intravenous labile iron, and positive calcium and phosphate balance), correction of high and low bone turnover, and restoration of anticalcification factor balance such as correction of vitamin D and K deficiency; parathyroid intervention is reserved for severe hyperparathyroidism. The role of bone antiresorption therapy such as bisphosphonates and denosumab in vascular calcification in high-bone-turnover disease remains unclear. The limited data on sodium thiosulfate are promising. However, if calcification is to be targeted, ensure that bone health is not compromised by the treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.